scholarly journals Pycnogenol® Supplementation Prevents Recurrent Urinary Tract Infections/Inflammation and Interstitial Cystitis

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
A. Ledda ◽  
S. Hu ◽  
M. R. Cesarone ◽  
G. Belcaro ◽  
M. Dugall ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Side Effects ◽  
Interstitial Cystitis ◽  
Urinary Tract Infections ◽  
Recurrent Uti ◽  
Recurrent Urinary Tract Infections ◽  
Standard Management ◽  
Tract Infections ◽  
Open Pilot

This open pilot registry study aimed to evaluate and compare the prophylactic effects of Pycnogenol® or cranberry extract in subjects with previous, recurrent urinary tract infections (UTI) or interstitial cystitis (IC). Methods. Inclusion criteria were recurrent UTI or IC. One subject group was supplemented with 150 mg/day Pycnogenol®, another with 400 mg/day cranberry extract, and a group served as a control in a 2-month open follow-up. Results. 64 subjects with recurrent UTI/IC completed the study. The 3 groups of subjects were comparable at baseline. All subjects had significant symptoms (minor pain, stranguria, repeated need for urination, and lower, anterior abdominal pain) at inclusion. In the course of the study, the subjects reported no tolerability problems or side effects. The incidence of UTI symptoms, in comparison with the period before inclusion in the standard management (SM) group, decreased significantly; there was a more pronounced decrease in the rate of recurrent infections in the Pycnogenol® group ( p < 0.05 ). The improvement in patients supplemented with Pycnogenol® was significantly superior to the effects of cranberry. At the end of the study, all subjects in the Pycnogenol® group were infection-free ( p < 0.05 vs. cranberry). Significantly, more subjects were completely symptom-free after 2 months of management with Pycnogenol® (20/22) than with SM (18/22) and cranberry (16/20). Conclusions. This pilot registry suggests that 60 days of Pycnogenol® supplementation possibly decrease the occurrence of UTIs and IC without side effects and with an efficacy superior to cranberry.

Extended Therapy with a Trimethoprim-Sulphonamide for the Treatment of Established Urinary Tract Infection

1971 ◽  
Vol 16 (12) ◽  
pp. 506-508 ◽  
Author(s):  
H. Gavras ◽  
D. H. Lawson ◽  
A. L. Linton
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Success Rate ◽  
Urinary Tract Infections ◽  
Allergic Reactions ◽  
Extended Treatment ◽  
Recurrent Urinary Tract Infections ◽  
Tract Infections

Thirty patients with recurrent urinary tract infections who had failed to respond to previous extended treatment with Sulphadimidine and/or Ampicillin were treated with a Trimethoprim-sulphamethoxazole combination ‘Septrin’. Twenty six per cent developed allergic reactions. In those who completed a 3-months' course there was a 59 per cent success rate in eradicating bacteriuria at a 6-months follow-up.

scholarly journals A Retrospective Study of Immunotherapy Treatment with Uro-Vaxom (OM-89®) for Prophylaxis of Recurrent Urinary Tract Infections

2020 ◽  
Vol 14 (3) ◽  
pp. 130-134
Author(s):  
Andrew Brodie ◽  
Omar El-Taji ◽  
Ibrahim Jour ◽  
Charlotte Foley ◽  
Damian Hanbury
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Primary Outcome Measure ◽  
Effective Treatment Option ◽  
Recurrent Utis ◽  
Recurrent Uti ◽  
Recurrent Urinary Tract Infections ◽  
Pre Treatment ◽  
The Uk ◽  
Tract Infections

<b><i>Objectives</i></b>: To present our experience with the long-term preventive effect of immunotherapy with Uro-Vaxom® on recurrent urinary tract infections (UTI) in adult patients. <b><i>Materials and Methods</i></b>: Retrospective analysis of 79 patients with recurrent UTI treated with Uro-Vaxom. Recurrent UTIs were defined as ≥ 2 infections in 6 months or ≥ 3 in 12 months. Patients received a 6 mg Uro-Vaxom capsule daily for 90 days followed by discontinuation for 3 months and then administration for the first 10 days of subsequent months 7, 8 and 9 as a ‘booster' regime. The primary outcome measure was the number of UTIs encountered in the 12 months pre-treatment compared to 12 months post-treatment. <b><i>Results</i></b>: There was a significant decrease in the mean number of UTIs in the year following initiation of Uro-Vaxom® compared to the year preceding administration 3.14 versus 1.53 (p < 0.05) respectively. <b><i>Conclusion</i></b>: Uro-Vaxom represents a safe and effective treatment option for prophylaxis of recurrent UTIs. In the UK, Uro-Vaxom is currently unlicensed. This study adds to a growing body of evidence in favor of non-antibiotic immune-prophylaxis for recurrent UTI.

Features of the vaginal microbiota in recurrent urinary tract infections in childhood

2021 ◽  
Vol 25 (6) ◽  
pp. 76-80
Author(s):  
Yu. Yu. Chebotareva ◽  
G. M. Letifov ◽  
Z. A. Kostoeva ◽  
E. I. Loginov ◽  
M. Yu. Tangieva
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
The State ◽  
Preschool Age ◽  
Control Group ◽  
Recurrent Uti ◽  
Facultative Anaerobes ◽  
Recurrent Urinary Tract Infections ◽  
The Absolute ◽  
Tract Infections

BACKGROUND. Currently, there is a stable deterioration in the somatic health of preschool-age girls, which creates a real threat to the realization of reproductive function in the future. The state of vaginal microbiocenosis in preschool girls suffering from recurrent urinary tract infections (UTIs) remains a little-studied problem.THE AIM: to assess the state of the vaginal biotope in preschool girls suffering from recurrent UTIs.PATIENTS AND METHODS. 92 girls aged 3-6 years were examined, of which: group 1 (n=32) - patients with recurrent UTI; group 2 (n=30) - patients with rare UTI; group 3 (n=30) - girls of 1,2 health groups. Vaginal microbiocenosis was assessed by quantitative PCR using the «Femoflor-17 test system». Statistical analysis was performed using the application program "Statistica 6.0 for Windows".RESULTS. Facultative anaerobes predominate in the vaginal microbiocenosis of patients with UTI, the absolute content of which is significantly higher in patients with the recurrent course (p <0.05). The relative number of facultative anaerobes is significantly higher in patients with rare UTIs (p<0.05). In patients with recurrent UTI, the absolute and relative content of obligate anaerobes is lower than in patients with rare UTI and girls from the control group. The index of total bacterial mass in patients with UTI, compared with girls of the control group, is significantly higher (p<0.05). In patients with UTI, an increase in the colonies of the Enterobacteriacea family and a decrease in obligate anaerobes were determined in comparison with similar indicators of girls in the control group.CONCLUSION. The presence of recurrent UTI in preschool girls is a risk factor for the development of the severe vaginal dysbiotic condition. Rare UTIs can also be a risk of developing vaginal dysbiosis. Real-time multi-dimensional PCR provides quantitative and qualitative characteristics of the conditionally pathogenic flora of the vaginal biotope.

scholarly journals Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: Results from a multicentre survey

2014 ◽  
Vol 8 (9-10) ◽  
pp. 721 ◽  
Author(s):  
Antonio Cicione ◽  
Francesco Cantiello ◽  
Giuseppe Ucciero ◽  
Andrea Salonia ◽  
Marco Torella ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hyaluronic Acid ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Chondroitin Sulphate ◽  
Recurrent Utis ◽  
Recurrent Urinary Tract Infections ◽  
Tract Infections

Introduction: We assess the effectiveness of intravesical instillation of hyaluronic acid (HA) and chondroitin sulphate (CS) as a non-antibiotic treatment option for prophylaxis of recurrent urinary tract infections (UTIs) in female patients.Methods: This was a retrospective cohort study involving 7 European institutions. We included patients with recurrent UTIs who received intravesical instillations of Ialuril (IBSA International) (50 mL HA 1.6% and CS 2% solution) between January 2010 and March 2012. Medication schedule, length of follow-up, recurrence infection time, number of UTIs/patients/year, patient quality of life, subjective symptoms score, and treatment-emergent side effects were recorded and analyzed.Results: In total, 157 women (mean age: 54.2 ± 4.1 years) were included in the analysis. All patients had at least 12 months follow-up. After 4 weekly and 5 monthly HA-CS bladder instillations, UTI episodes decreased from 4.13 ± 1.14 to 0.44 ± 0.50 (p = 0.01) at 12 months, while recurrent UTI time prolonged from 94.8 ± 25.1 days to 178.4 ± 37.3 days (p = 0.01) at 12 months. An improvement in symptoms and quality of life was achieved. A medium-depth pain after medication instillation was the most reported side effect. Regression model analysis showed significant risk factors in developing new UTI episodes: being more than 50 years old and having more than 4 UTI episodes per year (OR 3.41; CI 95%; 1.51-7.71, p = 0.003 and OR 3.31; CI 95% 1.51-7.22; p = 0.003, respectively). Retrospective design and lack of a control group represent two main limitations of the study.Conclusions: Restoring glycosaminoglycans bladder layer therapy is a promising non-antibiotic therapy to prevent recurrent UTIs.

Urodynamics for Recurrent Urinary Tract Infections after Kidney Transplant: a Case Series

2019 ◽  
Author(s):  
Adarsh Manjunath ◽  
Elodi J. Dielubanza ◽  
Channa Amarasekera ◽  
Stephanie J. Kielb
Keyword(s):  
Urinary Tract ◽  
Renal Transplant ◽  
Urinary Tract Infections ◽  
Medical Therapy ◽  
Significant Proportion ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Recurrent Urinary Tract Infections ◽  
Tract Infections

Abstract Background A significant proportion of renal transplant recipients experience recurrent urinary tract infections. This can ultimately compromise graft function but no protocol exists for diagnosis and management in these patients. We sought to evaluate the utility of urodynamics in renal transplant recipients with recurrent urinary tract infections. Methods Our institution’s electronic data warehouse was queried to identify renal transplant recipients who received urodynamics between 1999 and 2013. A retrospective review of urodynamic findings, management, and graft outcomes was performed for nine patients who had a diagnosis of recurrent urinary tract infections. Mean follow-up was 2.46 years. Results On urodynamics, mean bladder capacity was 392mL and post-void residual urine volume was >100mL in 3/9 patients. All patient had normal bladder compliance and voiding pressures. Native ureteral reflux was seen in one patient with a history of a febrile urinary tract infection and 4/9 had reflux in a transplant kidney. Mean creatinine at last follow up was 1.47. The patient with febrile infections had creatinine >3 from a nadir of <1. All patients were managed with medical therapy and none referred for surgery. No patients required dialysis. Conclusions In renal transplant recipients with recurrent urinary tract infections and no pre-existing voiding abnormalities, urodynamics did not identify functional or anatomic abnormalities that impacted management. Urodynamics may have a limited role as a diagnostic modality in this cohort after failure to respond to medical therapy.

Sign in / Sign up

Export Citation Format

Share Document